Corvus is the founding and majority shareholder of Manoira Corporation, a specialty animal treatment company focused on developing proprietary intellectual property using solid form technology. Manoira specialise in the research and development of pharmaceutical and other health products for livestock and pets and intend to develop their portfolio of products to prevent and treat a variety of animal diseases and conditions.
Corvus is the founding and majority shareholder of Conduit Pharmaceuticals, a disease agnostic life science company providing an efficient model for compound development. Conduit successfully completed a business combination with Murphy Canyon Acquisition Corp. in September 2023 for a proforma enterprise value of approximately $720 MM.
Corvus Capital is pleased to have advised Taylor Partners, the activist shareholder of East Imperial plc (LON: EISB), alongside Strand Hanson, on Taylor Partner's successful proposition to make a number of Board changes at EISB.
Corvus is the founding shareholder of Ebers Tech Inc., a private Canadian pharmaceutical company that utilises Co-crystallization and other technology to generate and monetize unique patented compounds and Intellectual Property around cannabinoids and psychedelics.
Corvus acquired a controlling interest and Board control of IB Daiwa Corporation, a multinational business conglomerate with headquarters in Tokyo. Following the execution of such Board changes, IB Daiwa Corporation increased its market capitalisation to over US$1 Billion.